Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 15/20 | 0.53 |
| ▸ | MMP3 | P08254 | 10/20 | 0.53 |
| ▸ | MMP1 | P03956 | 9/20 | 0.53 |
| ▸ | MMP7 | P09237 | 5/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28058533 | 1.00 | CSNK1E (0.57) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL22558568 | 1.00 | CSNK1E (0.57) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL28081007 | 1.00 | CSNK1E (0.57) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL2187591 | 0.98 | CSNK1E (0.55) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL2719254 | 0.94 | CA1 (0.55) | CSNK1EMMP2MMP3MMP1FOLH1 | |
| SCHEMBL11357056 | 0.92 | FAAH (0.51) | CSNK1EMMP2MMP3MMP1 | |
| SCHEMBL18248575 | 0.92 | FAAH (0.51) | CSNK1EMMP2MMP3MMP1 | |
| SCHEMBL18248569 | 0.92 | FAAH (0.51) | CSNK1EMMP2MMP3MMP1 | |
| SCHEMBL18248544 | 0.89 | EPHX2 (0.53) | CSNK1E | |
| SCHEMBL10957172 | 0.87 | FOLH1 (0.66) | CSNK1EMMP2MMP3MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051184-A1 | METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES | NEUVOLA II, LLC | 2001-12-13 | — | — | US | disclosed |
| WO-2000070949-A1 | METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES | HENG MADALENE C Y (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051184-A1 | METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES | CAMK1, PNCK, CAMK1D | CSNK1E 381/4885MMP2 292/4885MMP3 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.